Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
Discover how FT839’s conditioning-free CAR T platform could reshape cancer and autoimmune treatment pathways. Read the full analysis now.
Why CUE-401’s IMMUNOLOGY2026 data could matter for autoimmune drug pipelines
Cue Biopharma, Inc. unveils new CUE-401 data. Find out what this means for autoimmune therapy development and the regulatory path ahead.
Could Hinge Bio, Inc. unlock a new class of lupus B-cell depletion therapies?
Hinge Bio, Inc. doses first subjects in HB2198 Phase 1 trial. Discover what this could mean for lupus treatment and next-generation immune reset therapies.
What Actuate Therapeutics’ Phase 2 survival data means for pancreatic oncology
Read how Actuate Therapeutics’ elraglusib survival data could reshape first-line pancreatic cancer treatment and what regulators may watch next.
How Cellectar Biosciences, Inc. is positioning CLR 125 for a differentiated TNBC treatment thesis
Cellectar Biosciences, Inc. begins CLR 125 Phase 1b in refractory TNBC. Read what this could mean for precision radioconjugate oncology.
Could Septerna open a new chapter in disease-modifying hypoparathyroidism treatment?
Could Septerna’s SEP-479 change hypoparathyroidism care? Read how this Phase 1 launch may reshape rare endocrine treatment pathways.
Can Lupin Limited gain ground in cardiometabolic generics with United States dapagliflozin launch?
Lupin Limited has launched generic dapagliflozin in the United States. Read what it means for Farxiga, pricing pressure, and market access.
Why Sobi’s EMPAVELI approval in Canada may change the rare kidney disease treatment landscape
Health Canada clears EMPAVELI for C3G and IC-MPGN. Read what this changes for nephrology treatment, market access, and rare kidney disease care.
Why the Terns acquisition matters more for Merck’s long-term pipeline strategy than its near-term revenue
Merck has begun its tender offer for Terns Pharmaceuticals. Read what the deal could change for metabolic drug competition and pipeline strategy.
Why electroCore, Inc.’s first PTSD patient enrollment could become a more important 2026 medtech catalyst than it first appears
electroCore, Inc. advances gammaCore in PTSD with first patient enrollment. Read why this 2026 medtech catalyst could matter more than it appears.